Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Trinity Biotech

Trinity Biotech develops, manufactures and markets diagnostic test kits for the clinical laboratory and point-of-care... read more Featured Products: More products

Download Mobile App




Rapid Syphilis Test Evaluated as Tool for Public Health Programs

By LabMedica International staff writers
Posted on 09 Nov 2016
A rapid commercial treponemal syphilis-screening test is a new tool for public health programs to combat increasing syphilis rates, specifically among persons without a prior syphilis infection.

The Syphilis Health Check (SHC) test can be performed by non-laboratorian healthcare personnel and results are available in 10 minutes and have recently received a Clinical Laboratory Improvement Amendments waiver.

Scientists at the Florida Department of Health (Tampa, FL, USA) in collaboration with The Centers of Disease Control and Prevention (CDC, Atlanta, GA, USA) evaluated the performance of SHC in comparison with treponemal and nontreponemal tests routinely used in its sexually transmitted disease (STD) clinic. More...
For this evaluation, patients seeking sexually transmitted diseases (STD) testing at the Florida Department of Health STD clinic in Escambia County during March 11 to April 21, 2016, were tested for syphilis using the SHC on blood specimens obtained by fingerstick; a venous blood specimen was drawn concurrently and submitted for treponemal and testing at the state public health laboratory.

Trep-Sure qualitative enzyme immunoassay (EIA) reference treponemal test was used as the standard for “true” positive or negative treponemal test results, when evaluating the SHC. The rapid plasma reagin (RPR) card for syphilis was also tested. The SHC was used to screen 202 patients for syphilis. Among these patients, 171 (85%) were nonreactive on all syphilis tests (SHC, EIA, and RPR), 26 (13%) had a reactive SHC, and five (2%) had a nonreactive SHC, but had one or more reactive tests at the state laboratory.

Among the 26 reactive SHCs, 10 (38%) had a reactive EIA (six had a reactive RPR), and 16 (62%) were not confirmed by EIA or RPR at the state laboratory. For the six reactive SHC patients with reactive EIA and reactive RPR, three were staged as secondary syphilis, one as primary syphilis, one as early latent syphilis, and one was a previously treated positive with no increase in titer since last testing. Among the five specimens that were reactive on other tests but SHC nonreactive, only one was both RPR (1:8 serum dilution) and EIA reactive. The sensitivity of SHC was 71.4% when compared with the Trep-Sure (EIA) reference treponemal test. The specificity of the SHC compared with the reference treponemal test was 91.5%. The study was published on October 28, 2016, in the journal Morbidity and Mortality Weekly Report.

Related Links:
Florida Department of Health
The Centers of Disease Control and Prevention

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.